Chad Beyer Joins GATC Health Corp’s Scientific Advisory Board to Enhance Drug Discovery Team

IRVINE, CA, Feb. 18, 2022—GATC Health, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced that Chad Beyer, PhD, MBA, has joined the company as Science Advisor to further enhance the drug discovery team. Dr. Beyer has nearly 25 years of experience in the discovery, research, and clinical development of disease-modifying medications. Currently, Dr. Beyer is Senior Vice President of Research and Development at Promentis Pharmaceuticals. Prior to heading up the R&D group at Promentis, Dr. Beyer was the SVP of R&D at Ariel Pharmaceuticals and Head of Neurochemistry at Wyeth Pharmaceuticals.

“Dr. Beyer’s proven leadership of successful preclinical and clinical drug discovery teams is a significant addition for GATC Health,” stated Dr. Jonathan Lakey, Chair of GATC Health’s Scientific Advisory Board. “His passion for GATC Health’s platform capabilities to accelerate the drug discovery process further validates our value.”

During his career, Dr. Beyer has led several preclinical and clinical drug discovery teams, participated in the submission of more than 33 INDs, and worked with a group responsible for contributing to the commercialization and life-cycle management of two blockbuster medications: Effexor® and Pristiq®.

Dr. Beyer holds a Ph.D. in neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. He has served on the Board of Directors of various companies including a non-profit organization focused on childhood cancer. Notably, Dr. Beyer has authored more than 70 manuscripts, co-edited the book entitled “Next Generation Antidepressants” and co-founded the journal “Technology Transfer & Entrepreneurship.” In addition, Dr. Beyer holds several adjunct faculty positions and is the ‘Entrepreneur in Residence’ at Lafayette College where he teaches Biotech Innovation, a course focused on entrepreneurship and “the business of science."

“Successfully translating pre-clinical findings to effective medicines for humans is difficult and hugely complex work. New tools to more efficiently and precisely discover a new generation of medicines are crucial and the team at GATC Health are at the leading-edge of such new AI and machine learning technologies,” stated Dr. Beyer. “I am excited to join GATC's Scientific Advisory Board to further advance their mission of developing AI-derived therapies for horrible and devastating diseases including addiction and substance use disorders.”

# # #

About GATC Health

GATC Health Corp is a pioneering technology company using whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company’s patented AI platform reduces risk, time and costs for life science companies by digitally reproducing the human body to find non-obvious answers to biology’s most complex questions. GATC Health is accelerating healthcare’s transition to predictive, individualized medicine.

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.